Qualitative Concept
Pfizer’s Subcutaneous PD-1 Inhibitor Sasanlimab Achieves Significant Efficacy in High-Risk Non-Muscle Invasive Bladder Cancer
Pfizer, Sasanlimab, Subcutaneous PD-1 inhibitor, Non-muscle invasive bladder cancer (NMIBC), BCG-naïve, Event-free survival (EFS), Combination therapy with BCG
FDA Sets Efficacy Threshold for Obesity Therapies Amid Market Expansion
FDA, obesity therapies, weight-loss treatments, efficacy standards, obesity market trends
Astellas Terminates Development of Autologous Cell Therapy for Lymphoma Following Pipeline Review
Astellas, lymphoma, CAR-T cell therapy, autologous cell therapy, pipeline review, cancer treatment, biotechnology
LB-102 Shows Promise as Potential First-in-Class Benzamide Antipsychotic for Schizophrenia in US
LB-102, schizophrenia, Phase 2 trial, benzamide antipsychotic, efficacy, safety
LB-102 Shows Promise as Potential First-in-Class Benzamide Antipsychotic for Schizophrenia
LB-102, schizophrenia, Phase 2 trial, benzamide antipsychotic, efficacy, safety
LB Pharma’s Phase II Success Revitalizes Benzamide Antipsychotics for US Schizophrenia Treatment
LB-102, schizophrenia, benzamide antipsychotics, Phase II trial, efficacy, safety
Novo Nordisk and Variant Bio Collaborate on Metabolic Disease Research, Focusing on Diverse Populations
Novo Nordisk, Variant Bio, Metabolic disease, Genetic research, Diverse populations, VB-Inference platform, Benefit-sharing program
FDA Approves First Generic Version of Victoza (Liraglutide) for Type 2 Diabetes Treatment
FDA approval, generic Victoza, liraglutide, GLP-1 receptor agonist, Type 2 diabetes treatment, affordable medication options
Novartis Achieves Pivotal Trial Success for Intrathecal Zolgensma in Older SMA Patients After FDA Delay
Novartis, Zolgensma, Intrathecal formulation, Spinal muscular atrophy (SMA), FDA approval, Pivotal phase 3 trial, Older SMA patients
Bristol Myers Squibb Marks Milestone with FDA Approval of Subcutaneous Opdivo Qvantig
Bristol Myers Squibb, Opdivo, subcutaneous administration, FDA approval, cancer treatment, immuno-oncology, PD-1 inhibitor.